Impact of Continuous Infusion Meropenem PK/PD Target Attainment on C-Reactive Protein Dynamics in Critically Ill Patients With Documented Gram-Negative Hospital-Acquired or Ventilator-Associated Pneumonia

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 2024 Oct 25

PMID 39455501

Authors

Carla Troisi

Pier Giorgio Cojutti

Matteo Rinaldi

Tommaso Tonetti

Antonio Siniscalchi

Coen van Hasselt

Pierluigi Viale

Federico Pea

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of antibiotics including C-reactive protein (C-RP) dynamics could be helpful in predicting the efficacy of antimicrobials. We developed a PK/PD model for assessing the impact of continuous infusion (CI) meropenem PK/PD target attainment on C-RP dynamics in critically ill patients with documented Gram-negative hospital- (HAP) or ventilator-acquired pneumonia (VAP).

Methods: Patients were grouped according to the type of antibiotic treatment received [meropenem monotherapy; meropenem plus empirical anti-MRSA (methicillin-resistant Staphylococcus aureus) therapy; meropenem in combination with another anti-Gram-negative active agent; meropenem plus a targeted anti-MRSA therapy]. A one-compartment population PK model of CI meropenem was developed by including all patients. A full C-RP production inhibition model was developed for fitting the PD data by including only patients receiving meropenem monotherapy or meropenem plus empirical anti-MRSA therapy. Monte Carlo simulations explored the relationship between the type of PK/PD target attainment of CI meropenem, defined as optimal (steady-state plasma concentration [C] to minimum inhibitory concentration [MIC] ratio = 4-8), quasi-optimal (C/MIC = 1-4) and sub-optimal (C/MIC < 1) and the magnitude of C-RP production inhibition over time.

Results: A total of 64 patients providing 211 meropenem concentrations were included in the PK analysis, whereas 47 patients providing 328 C-RP data were included in the PD model. Simulations showed that optimal PK/PD target attainment was associated with the highest and most rapid C-RP production inhibition (44% and 56% at days 2 and 4, respectively). Conversely, sub-optimal PK/PD target attainment was shown to be almost ineffective (< 5% at day 4 and < 10% at day 10).

Conclusion: Our PK/PD model predicted that attaining optimal PK/PD target with CI meropenem may grant prompt and intense C-RP decrease among critically ill patients receiving targeted monotherapy for Gram-negative HAP/VAP, thus anticipating efficacy.

References

Alshaer M, Maranchick N, Alexander K, Manigaba K, Shoulders B, Felton T . Beta-lactam target attainment and associated outcomes in patients with bloodstream infections. Int J Antimicrob Agents. 2023; 61(3):106727. DOI: 10.1016/j.ijantimicag.2023.106727. View

Cojutti P, Gatti M, Bonifazi F, Caramelli F, Castelli A, Cavo M . Impact of a newly established expert clinical pharmacological advice programme based on therapeutic drug monitoring results in tailoring antimicrobial therapy hospital-wide in a tertiary university hospital: Findings after the first year of.... Int J Antimicrob Agents. 2023; 62(2):106884. DOI: 10.1016/j.ijantimicag.2023.106884. View

Sanz Codina M, Gatti M, Troisi C, Fornaro G, Pasquini Z, Trapani F . Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem. Pharmaceutics. 2022; 14(8). PMC: 9412264. DOI: 10.3390/pharmaceutics14081585. View

Ogami C, Tsuji Y, Muraki Y, Mizoguchi A, Okuda M, To H . Population Pharmacokinetics and Pharmacodynamics of Teicoplanin and C-Reactive Protein in Hospitalized Patients With Gram-Positive Infections. Clin Pharmacol Drug Dev. 2019; 9(2):175-188. DOI: 10.1002/cpdd.684. View

Koiwai K, El-Cheikh R, Thai H, Brillac C, Fau J, Veyrat-Follet C . PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma. CPT Pharmacometrics Syst Pharmacol. 2021; 10(8):928-940. PMC: 8376141. DOI: 10.1002/psp4.12666. View

Metlay J, Waterer G, Long A, Anzueto A, Brozek J, Crothers K . Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019; 200(7):e45-e67. PMC: 6812437. DOI: 10.1164/rccm.201908-1581ST. View

Ulldemolins M, Soy D, Llaurado-Serra M, Vaquer S, Castro P, Rodriguez A . Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. Antimicrob Agents Chemother. 2015; 59(9):5520-8. PMC: 4538468. DOI: 10.1128/AAC.00712-15. View

Dhaese S, Van Vooren S, Boelens J, De Waele J . Therapeutic drug monitoring of β-lactam antibiotics in the ICU. Expert Rev Anti Infect Ther. 2020; 18(11):1155-1164. DOI: 10.1080/14787210.2020.1788387. View

Ramirez S, Scapaticci M, Barbella F, Panico M, Fecca I, Cocchini B . Development of a rapid LC-MS/MS method for simultaneous quantification of ten commonly used antibiotic drugs in human serum. J Pharm Biomed Anal. 2024; 244:116119. DOI: 10.1016/j.jpba.2024.116119. View

10.

Soeorg H, Padari H, Ilmoja M, Herodes K, Kipper K, Lutsar I . Prediction of C-reactive protein dynamics during meropenem treatment in neonates and infants. Br J Clin Pharmacol. 2023; 90(3):801-811. DOI: 10.1111/bcp.15950. View

11.

Gatti M, Cojutti P, Pea F . Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis. Crit Care. 2024; 28(1):123. PMC: 11020314. DOI: 10.1186/s13054-024-04911-5. View

12.

Franceschi L, Cojutti P, Baraldo M, Pea F . Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures. Ther Drug Monit. 2014; 36(5):674-6. DOI: 10.1097/FTD.0000000000000054. View

13.

Kalil A, Metersky M, Klompas M, Muscedere J, Sweeney D, Palmer L . Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016; 63(5):e61-e111. PMC: 4981759. DOI: 10.1093/cid/ciw353. View

14.

Mattioli F, Fucile C, Del Bono V, Marini V, Parisini A, Molin A . Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. Eur J Clin Pharmacol. 2016; 72(7):839-48. DOI: 10.1007/s00228-016-2053-x. View

15.

Cojutti P, Heffernan A, Tangden T, Della Siega P, Tascini C, Roberts J . Population Pharmacokinetic and Pharmacodynamic Analysis of Valganciclovir for Optimizing Preemptive Therapy of Cytomegalovirus Infections in Kidney Transplant Recipients. Antimicrob Agents Chemother. 2023; 67(3):e0166522. PMC: 10019259. DOI: 10.1128/aac.01665-22. View

16.

Sungurlu S, Balk R . The Role of Biomarkers in the Diagnosis and Management of Pneumonia. Infect Dis Clin North Am. 2024; 38(1):35-49. DOI: 10.1016/j.idc.2023.12.005. View

17.

Martson A, Sturkenboom M, Knoester M, van der Werf T, Alffenaar J, Hope W . Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads. J Antimicrob Chemother. 2022; 77(2):466-473. PMC: 8809194. DOI: 10.1093/jac/dkab419. View

18.

OJeanson A, Larcher R, Le Souder C, Djebli N, Khier S . Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation. Eur J Drug Metab Pharmacokinet. 2021; 46(5):695-705. DOI: 10.1007/s13318-021-00709-w. View

19.

Blot S, Ruppe E, Harbarth S, Asehnoune K, Poulakou G, Luyt C . Healthcare-associated infections in adult intensive care unit patients: Changes in epidemiology, diagnosis, prevention and contributions of new technologies. Intensive Crit Care Nurs. 2022; 70:103227. PMC: 8892223. DOI: 10.1016/j.iccn.2022.103227. View

20.

Gatti M, Cojutti P, Pascale R, Tonetti T, Laici C, DellOlio A . Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections. Antibiotics (Basel). 2021; 10(11). PMC: 8615220. DOI: 10.3390/antibiotics10111311. View